Synonyms: 17-AAG | 17-allylamino-17-demethoxygeldanamycin | 17-N-allylamino-17-demethoxygeldanamycin | 17AAG | compound 4 [PMID:15978816]
Compound class:
Synthetic organic
Comment: 17-AAG inhibits the activity of hsp90. The compound is a derivative of the antibacterial geldanamycin.
As with other natural products, there is some ambiguity in the absolute stereochemistry annotated by different online resources. PubChem records an alternative isomer with a Z bond at position 12 which has CID 6505803. 17-AAG acts as a femtomolar inhibitor of Met tyrosine kinase receptor-dependent urokinase-plasminogen activation [5]. |
|
No information available. |
Summary of Clinical Use ![]() |
The EMA has granted orphan drug designation for this compound as a treatment for malignant gastrointestinal stromal tumours (GIST), chronic myeloid leukemia (CML, and the FDA for the same indication) and multiple myeloma (MM). 17-AAG was investigated as a potential antineoplastic therapy [2]. Click here to link to ClinicalTrials.gov's list of registered tanespimycin trials. There are no currently active trials (Sept 2014). |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
17-AAG binds to the common N-terminal domain ATP/ATP binding site on both α and β Hsp90 isoforms. This destabilises Hsp90 client proteins, a number of which are oncogenic, and cells undergo apoptosis [1]. |